Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma

NCT06771934 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Allergic Asthma

Interventions

BIOLOGICAL: Allergen-specific immunotherapy(AIT)
BIOLOGICAL: omalizumab

Sponsor

Qianfoshan Hospital